About us

Iconovo develops inhaler platforms at its own risk, with patent protection sought for all unique designs. Additionally, we usually advance suitable formulations and drug candidates up to pre-clinical PoC (Proof of Concept) or pilot PK (Pharmacokinetic) studies, before seeking partnerships for late-stage development and commercialization.

Revenue is primarily generated through upfront and milestone payments from partners during development, followed by royalties once the product reaches the market.

For interchangeable generic products, Iconovo generally retains rights for direct sales in the Nordics, as well as the mandate to manufacture and supply the inhalers. This arrangement offers a practical and economic solution for partners while providing a source of continuous income for Iconovo.

Iconovo offers smart and reliable products that help people with respiratory and other diseases manage their conditions and improve their health. While inhaled medicines are historically mainly associated with asthma and COPD, they can be applied in any therapy area to replace injections with a more patient-friendly administration form. Currently, Iconovo’s active projects outside of the respiratory area include for example:

● Obesity (semaglutide)
● Vaccination
● Post partum hemorrhage (oxytocin)

The lung is a particularly effective route of administration for peptides and larger molecules, as these are otherwise extensively degraded in the gut. An added benefit of Dry Powder Inhalation is that the formulation is often less sensitive to high temperatures and temperature variations, eliminating the need for refrigeration in transport and storage.